Steven Poynter

Prior to joining Goodwin, Dr. Poynter was a science advisor at a Boston-area firm. Dr. Poynter has also served as a Business Development Fellow with the Harvard University Office of Technology Development. As a Business Development Fellow, he assessed market size, IP landscape, competition, and partnering strategies for a diverse portfolio of technologies developed at Harvard University.

Dr. Poynter received his PhD in Chemical Biology from Harvard University, where he specialized in the field of epigenetics. For his dissertation work, he investigated oncogenic combinatorial assembly mechanisms of mammalian SWI/SNF complexes in malignant rhabdoid tumor (MRT) and clear cell renal cell carcinoma (ccRCC). As a graduate student, he also conducted extensive research on the epigenetic complexes PRC1 and PRC2. Prior to graduate school, Dr. Poynter investigated T-reg and exosome biomarkers associated with lung transplant rejection at University of California, Los Angeles. In addition, he conducted research on several small molecule inhibitors of butyrylcholinesterase for the treatment of Alzheimer’s Disease at California State University, Long Beach.

• Co-Author, “Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes,” Cell, 2018.
• Author, “Polycomb and trithorax Opposition in Development and Disease,” WIREs Dev. Biol., 2016.
• Co-Author, “Altered Exosomal RNA Profiles in Bronchoaveolar Lavage from Lung Transplant Recipients with Acute Rejection,” Am. J. Respir. Crit. Care Med., 2015.
• Speaker, “Navigating A Career Toward Scientific Discovery,” Bunker Hill Community College, Boston, MA, November 2014.
• Co-Author, “Di-Alkyl Aryl Phosphate Inhibitors Of Butyrylcholinesterase As A Potential Therapeutic For The Treatment Of Alzheimer’s Disease: Characteristics Of Off-Target Effects,” CUR: Posters on the Hill, 2011.